Skip to main content
    J

    Jazz Pharmaceuticals PLC (JAZZ)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $239.77
    -1.78 (-0.74%)

    Market Cap: $15.50B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Jazz Pharmaceuticals PLC (JAZZ) Earnings: Report Dates and Results

    Updated Nov 2, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Jazz Pharmaceuticals (JAZZ) is expected to report earnings on Feb 22, 2027. In the quarter ended Sep 30, 2026, Jazz Pharmaceuticals reported EPS of -$4.83, above the -$5.18 estimate. It beat the EPS estimate in 5 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    65%(26/40)
    Avg Surprise
    +0.64%
    Streak
    1 Q

    Upcoming Estimates

    Reports Feb 22, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$7.12
    Range$5.19 - $13.32
    22 analysts
    Revenue Consensus
    $1.30B
    Range$1.20B - $1.39B
    20 analysts
    Reports May 3, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$5.89
    Range$4.88 - $6.70
    6 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$5.64+4.4%
    60d ago$5.65+4.2%
    30d ago$5.65+4.2%
    7d ago$6.26-5.9%
    Current$5.89
    Revenue Consensus
    $1.14B
    Range$1.12B - $1.17B
    4 analysts

    Next Report

    JAZZ has an expected report date of Feb 22, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 7.2% above the $6.64 reported for the quarter ended Dec 31, 2025.

    JAZZ Earnings Call

    The latest JAZZ earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, JAZZ beat 26 and missed 14. Revenue for the quarter ended Sep 30, 2026 was $1.24B, up 9.7% from $1.13B a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$4.83-$5.18N/A+6.76%Beat-169.1%130 up, 10 downNov 2, 2026$1.24B
    Jun 30, 2026$4.89$5.06N/A-3.36%MissN/A170 up, 2 downAug 3, 2026$1.21B
    Mar 31, 2026$6.34$4.66$3.75 - $5.62+36.05%Beat+277.4%155 up, 2 downMay 5, 2026$1.07B
    Dec 31, 2025$6.64$6.51$5.95 - $7.55+2.05%Beat+0.6%136 up, 2 downFeb 24, 2026$1.20B
    Sep 30, 2025$6.99$4.80N/A+45.63%Beat+5.7%161 up, 4 downNov 5, 2025$1.13B
    Jun 30, 2025-$8.25-$6.25-$9.61 - $4.47-32.00%Miss-255.7%164 up, 3 downAug 5, 2025$1.05B
    Mar 31, 2025$1.68$4.66$3.70 - $5.87-63.95%Miss-37.3%161 up, 4 downMay 6, 2025$897.80M
    Dec 31, 2024$6.60$5.81$5.00 - $6.49+13.58%Beat+31.5%173 up, 2 downFeb 25, 2025$1.09B
    Sep 30, 2024$6.61$5.50$4.93 - $5.93+20.18%Beat+36.6%172 up, 1 downNov 6, 2024$1.05B
    Jun 30, 2024$5.30$4.78$4.23 - $5.78+10.88%Beat+17.5%171 up, 2 downJul 31, 2024$1.02B
    Mar 31, 2024$2.68$4.18$3.73 - $4.83-35.89%Miss-32.2%162 up, 2 downMay 1, 2024$901.98M
    Dec 31, 2023$5.02$5.18$4.75 - $5.62-3.09%MissN/A152 up, 0 downFeb 28, 2024$1.01B
    Sep 30, 2023$4.84$4.93$4.44 - $5.19-1.83%Miss-6.4%152 up, 1 downNov 8, 2023$972.14M
    Jun 30, 2023$4.51$4.43$3.93 - $4.92+1.81%Beat+4.9%152 up, 0 downAug 9, 2023$957.32M
    Mar 31, 2023$3.95$4.22$3.73 - $5.02-6.40%Miss+5.9%161 up, 0 downMay 10, 2023$892.81M
    Dec 31, 2022-$0.07$0.32-$0.46 - $0.88-121.88%Miss-101.7%130 up, 2 downMar 1, 2023$972.12M
    Sep 30, 2022$5.17$4.67$4.11 - $4.98+10.71%Beat+23.1%163 up, 0 downNov 9, 2022$940.65M
    Jun 30, 2022$4.30$4.19$3.32 - $4.70+2.63%Beat+10.3%163 up, 1 downAug 3, 2022$932.88M
    Mar 31, 2022$3.73$3.89$3.06 - $4.62-4.11%Miss-4.8%163 up, 0 downMay 4, 2022$813.72M
    Dec 31, 2021$4.21$3.64$3.05 - $3.94+15.66%Beat+5.2%181 up, 1 downMar 1, 2022$896.73M
    Sep 30, 2021$4.20$3.31$2.88 - $3.69+26.89%Beat-2.6%151 up, 0 downNov 9, 2021$838.12M
    Jun 30, 2021$3.90$3.45$2.00 - $4.26+13.04%Beat+5.1%13N/AAug 3, 2021$751.81M
    Mar 31, 2021$3.92$3.73$3.32 - $4.07+5.09%Beat+771.1%18N/AMay 4, 2021$607.58M
    Dec 31, 2020$4.00$4.20$3.82 - $5.10-4.76%Miss-9.5%18N/AFeb 23, 2021$665.52M
    Sep 30, 2020$4.31$4.08$3.92 - $4.34+5.64%Beat+5.1%17N/ANov 2, 2020$600.89M
    Jun 30, 2020$3.71$3.11$1.71 - $3.67+19.29%Beat-8.4%16N/AAug 4, 2020$562.44M
    Mar 31, 2020$0.45$0.67$0.31 - $1.14-32.84%Miss-87.7%15N/AMay 5, 2020$534.73M
    Dec 31, 2019$4.42$4.12$3.93 - $4.33+7.28%Beat+21.4%17N/AFeb 25, 2020$581.74M
    Sep 30, 2019$4.10$3.59$3.48 - $3.76+14.21%Beat+14.5%16N/ANov 5, 2019$537.70M
    Jun 30, 2019$4.05$3.57$3.35 - $3.69+13.45%Beat+16.0%17N/AAug 6, 2019$534.13M
    Mar 31, 2019$3.67$3.16$2.96 - $3.51+16.14%Beat+23.2%16N/AMay 7, 2019$508.19M
    Dec 31, 2018$3.64$3.02$2.81 - $3.36+20.53%Beat+23.4%18N/AFeb 26, 2019$476.46M
    Sep 30, 2018$3.58$3.32$3.14 - $3.47+7.83%Beat+11.2%18N/ANov 6, 2018$469.37M
    Jun 30, 2018$3.49$3.21$3.11 - $3.35+8.72%Beat+36.3%21N/AAug 7, 2018$500.48M
    Mar 31, 2018$2.98$2.78$2.54 - $3.08+7.19%Beat+29.0%22N/AMay 8, 2018$444.61M
    Dec 31, 2017$2.95$2.98$2.76 - $3.56-1.01%Miss+8.9%23N/AFeb 27, 2018$436.40M
    Sep 30, 2017$3.22$2.89$2.78 - $3.01+11.42%Beat+25.3%20N/ANov 7, 2017$411.86M
    Jun 30, 2017$2.56$2.75$2.63 - $2.89-6.91%Miss-2.7%16N/AAug 8, 2017$394.39M
    Mar 31, 2017$2.31$2.34N/A-1.28%Miss+2.2%N/AN/AMay 9, 2017$376.05M
    Dec 31, 2016$2.71$2.65N/A+2.26%Beat+4.2%N/AN/AFeb 28, 2017$396.62M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $7.06, down 66.7% from the year before. It was $10.17 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$7.06-66.7%
    Dec 31, 2024$21.19+15.7%
    Dec 31, 2023$18.32+39.5%
    Dec 31, 2022$13.13-19.1%
    Dec 31, 2021$16.23+30.2%
    Dec 31, 2020$12.47-23.2%
    Dec 31, 2019$16.24+18.6%
    Dec 31, 2018$13.69+24.0%
    Dec 31, 2017$11.04+8.6%
    Dec 31, 2016$10.17N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,100 words across 21 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20268,12221
    2026Q2Jun 30, 20266,42421
    2026Q1Mar 31, 20268,00818
    2025Q4Dec 31, 20258,12219
    2025Q3Sep 30, 20257,91422
    2025Q2Jun 30, 20259,08720
    2025Q1Mar 31, 20258,90320
    2024Q4Dec 31, 20249,59219

    2026Q3 Earnings Call

    Opening remarks

    John Bluth Head of Investor Relations Thank you, and good afternoon, everyone. Today, Jazz Pharmaceuticals reported its third quarter 2026 financial results. The slide presentation accompanying this webcast is available on the Investors section of our website, along with the press release and quarterly report on Form 10-Q for the quarter ended September 30, 2026. On the call today are Renee Gala, President and Chief Executive Officer; Sam Pearce, Chief Commercial Officer; Robbie Iannone, Global Head of R&D and Chief Medical Officer; and Phil Johnson, Chief Financial Officer. On Slide 2, I'd like to remind you that today's webcast includes forward-looking statements, such as those related to our future financial and operating results, growth potential and anticipated development, regulatory and commercial milestones, which involve risks and uncertainties that could cause actual events, performance and results to differ materially from those contained in these forward-looking statements. We encourage you to review these risks and uncertainties described in today's press release and under the caption Risk Factors in our annual report on Form 10-K for the fiscal year ended December 31, 2025, and quarterly report on Form 10-Q for the quarter ended September 30, 2026. We undertake no duty or obligation to update our forward-looking statements. Furthermore, we will discuss non-GAAP financial measures on this webcast. Descriptions of these non-GAAP financial measures and reconciliations of GAAP to non-GAAP financial measures are included in today's press release and the slide presentation available on the Investors section of our website. I'll now turn the call over to Renee.

    Renée Galá President and Chief Executive Officer Thank you, John. Good afternoon, everyone, and thank you for joining us today. Our third quarter results demonstrate the progress we are making as we build a more innovative and diversified Jazz. We delivered record revenues of $1.24 billion, an increase of 10% year-over-year, while advancing several important drivers of our future growth. Most notably, the FDA approval and launch of Ziihera in first-line HER2-positive metastatic GEA was a defining milestone for Jazz, establishing an important new source of growth and marking the beginning of what we believe could be a much broader opportunity across HER2-expressing cancers. And as you'll hear from Sam, the launch is off to a fantastic start. Longer-term data presented at ESMO further strengthen our conviction in Ziihera, and we continue to see peak sales potential of $3 billion to $5 billion. Our commercial portfolio is performing well, with multiple products contributing to our growth. Oncology revenues grew 35% year-over-year, driven by the launches of Modeyso and Zepzelca in the first-line maintenance setting, while sustained demand for Xywav continued to underscore its durability and differentiation. Given our third quarter performance, we have increased our 2026 revenue guidance, as Phil will outline later in the call.

    Frequently Asked Questions About JAZZ

    When is Jazz Pharmaceuticals's next earnings date?

    Jazz Pharmaceuticals's next earnings report is expected for Feb 22, 2027.

    Did JAZZ beat earnings estimates last quarter?

    Yes. Jazz Pharmaceuticals reported EPS of -$4.83 for the quarter ended Sep 30, 2026, above the -$5.18 estimate, a 6.76% surprise.

    What EPS do analysts expect from JAZZ next quarter?

    The consensus EPS estimate for Jazz Pharmaceuticals for the quarter ending Dec 31, 2026 is $7.12 from 22 analysts, with estimates from $5.19 to $13.32.

    How often does JAZZ beat earnings estimates?

    Jazz Pharmaceuticals beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +0.60%.